Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P 500 volatile in choppy trading; Mideast deal, SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Allogene Therapeutics Reports Second Quarter 2022 Financial Results
August 9, 2022 4:02 PM EDTU.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industrys First Allogeneic CAR T Phase 2 Pivotal TrialClearance to Cover ALPHA2 Protocol and Chemistry Manufacturing and Controls (CMC) for Use of ALLO-501A Manufactured from Cell Forge 1 (CF1)CF1 is Projected to Support the Manufacture of ~20,000 Doses of AlloCAR T Products Annually at Scale CF1 Earned a LEED® Interior Design and Construction Gold Designation from the U.S Green Building CouncilCompany Plans to Evaluate Potential Phase 2... More
